Filing Flows › Novo Nordisk A S (NVO) › Capital expenditures
Novo Nordisk A S (NVO) capital expenditures by quarter
Novo Nordisk A S' capital expenditures were $13.2B in Q3 2026 (third quarter 2026), +4% from Q2 2026. Over the last 6 quarters it ranged from $11.3B (Q1 2026) to $18.4B (Q4 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $13.2B | +4% | -3% |
| Q2 2026 | $12.7B | +12% | -14% |
| Q1 2026 | $11.3B | -39% | — |
| Q4 2025 | $18.4B | +35% | — |
| Q3 2025 | $13.6B | -7% | — |
| Q2 2025 | $14.7B | — | — |
Q3 2026 at a glance
Novo Nordisk A S, Q3 2026: revenue $79.2B (+6% year over year), operating margin 29.1%, net earnings $16.7B, operating cash flow $41.7B. The chart follows the revenue to costs, profit and cash.
Questions
What is Novo Nordisk A S' capital expenditures?
Novo Nordisk A S' capital expenditures were $13.2B in Q3 2026 (third quarter 2026), +4% from Q2 2026.
How has Novo Nordisk A S' capital expenditures changed?
Over the last 6 quarters it ranged from $11.3B (Q1 2026) to $18.4B (Q4 2025).